| 1JMQ |
|
YAP65 (L30K mutant) WW domain in Complex with GTPPPPYTVG peptide |
| 1K5R |
|
YAP65 WW domain S24-Amino-Ethylsulfanyl-Acetic Acid mutant |
| 1K9Q |
|
YAP65 WW domain complexed to N-(n-octyl)-GPPPY-NH2 |
| 1K9R |
|
YAP65 WW domain complexed to Acetyl-PLPPY |
| 2LAW |
|
Structure of the second WW domain from human YAP in complex with a human Smad1 derived peptide |
| 2LAX |
|
Structure of first WW domain of human YAP in complex with a human Smad1 doubly-phosphorilated derived peptide. |
| 2LAY |
|
Structure of the first WW domain of human YAP in complex with a phosphorylated human Smad1 derived peptide |
| 2LTV |
|
YAP WW2 in complex with a Smad7 derived peptide |
| 2LTW |
|
YAP WW1 in complex with a Smad7 derived peptide |
| 3KYS |
2.8 |
Crystal structure of human YAP and TEAD complex |
| 3MHR |
1.15 |
14-3-3 sigma in complex with YAP pS127-peptide |
| 4RE1 |
2.2 |
Crystal structure of human TEAD1 and disulfide-engineered YAP |
| 4REX |
1.6 |
Crystal structure of the first WW domain of human YAP2 isoform |
| 5OAQ |
1.95 |
TEAD4 COMPLEXED WITH YAP PEPTIDE AND MYRISTATE (COVALENTLY BOUND) |
| 5YDX |
|
NMR structure of YAP1-2 WW1 domain with LATS1 PPxY motif complex |
| 5YDY |
|
NMR structure of YAP1-2 WW2 domain with LATS1 PPxY motif complex |
| 6G6X |
1.13 |
14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide |
| 6G8I |
1.6 |
14-3-3sigma in complex with a R124beta3R mutated YAP pS127 phosphopeptide |
| 6G8J |
1.47 |
14-3-3sigma in complex with a A130beta3A mutated YAP pS127 phosphopeptide |
| 6G8K |
1.25 |
14-3-3sigma in complex with a S131beta3S mutated YAP pS127 phosphopeptide |
| 6G8L |
1.37 |
14-3-3sigma in complex with a L132beta3L mutated YAP pS127 phosphopeptide |
| 6G8P |
1.9 |
14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide |
| 6G8Q |
1.85 |
14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide |
| 6GE3 |
1.85 |
X-ray structure of TEAD4 (wildtype) complexed with YAP (wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface |
| 6GE4 |
1.97 |
TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 1.97A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6GE5 |
2.05 |
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6GE6 |
1.8 |
X-ray structure of TEAD4(E263A+Y429F mutant) complexed with YAP(wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface |
| 6GEC |
1.7 |
TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100);S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.70A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6GEE |
1.96 |
TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6GEG |
2.23 |
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 2.23A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6GEI |
1.65 |
TEAD4 (216-434);E263A+Y429F COMPLEXED WITH YAP PEPTIDE (60- 100);S94A AND MYRISTOATE (COVALENTLY BOUND TO LYS344, NOT CYS367!) AT 1.65A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6GEK |
2.28 |
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28A (P212121 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA |
| 6HIK |
1.65 |
X-ray structure of TEAD4(Y429H) mutant) complexed with YAP (wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy |
| 6HIL |
2.3 |
X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy |
| 6Q2X |
2.1 |
TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.1A (P41212 CRYSTAL FORM) |
| 7O07 |
1.2 |
14-3-3sigma covalently bound to peptide (chloroacetamide-Cys interaction) |
| 8A8Q |
1.465 |
Crystal structure of Protein Scalloped in complex with YAP peptide |
| 8A8R |
1.696 |
Crystal structure of TEAD4 in complex with YAP peptide |
